Rance lining up for her 27th go at tourney
Lyn Rance keeps rolling on.
The Green Island bowler is the only player to have been involved in the Southern zone women's eights tournament since its inception in 1998 and this weekend will be no different.
Rance is lining up for her 27th tournament with the Otago team at the Dunedin Indoor Bowls Stadium.
"I was the original one. I'm the only one that's played right through," Rance said.
"I just so enjoy meeting the people that you've met over the years. You make a lot of friends and it's just a great competition among ladies — it's just brilliant."
The annual tournament features teams from Otago, South Canterbury, North Otago, South Otago, Central Otago and Southland, and is returning to Dunedin for the first time in six years.
Southland have been the leaders through the years, notching 12 wins and winning the tournament for the past three years.
Otago, who have won the tournament seven times and last held the trophy in 2019, are packed with talent.
Keri Te Tamaki, who captained the South Island team last year, is suiting up alongside fellow South Island representative Tracey Van Tuel.
Van Tuel is also playing alongside her sister, Amanda Kapita, and Kapita's daughter, Poppy, 18, is also in the team.
There is power across all the teams including former South Island representatives Alanna Moffitt, from South Otago, and Suzanne Mackie, from Southland, who is also a former national representative.
Each district has eight players split into two teams of four.
Each player plays five games of singles, pairs, and fours across the two days.
At the end, the points for both teams of fours are combined and the district with the most points is the winner.
Play gets under way at 8.30am today and the final games should be finished by mid-afternoon tomorrow.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So should INOVIQ (ASX:IIQ) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How Long Is INOVIQ's Cash Runway? You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at December 2024, INOVIQ had cash of AU$9.5m and no debt. Looking at the last year, the company burnt through AU$4.7m. That means it had a cash runway of about 2.0 years as of December 2024. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below. View our latest analysis for INOVIQ How Well Is INOVIQ Growing? On balance, we think it's mildly positive that INOVIQ trimmed its cash burn by 17% over the last twelve months. But the revenue dip of 17% in the same period was a bit concerning. In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years. How Easily Can INOVIQ Raise Cash? Even though it seems like INOVIQ is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Since it has a market capitalisation of AU$44m, INOVIQ's AU$4.7m in cash burn equates to about 11% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution. So, Should We Worry About INOVIQ's Cash Burn? Even though its falling revenue makes us a little nervous, we are compelled to mention that we thought INOVIQ's cash runway was relatively promising. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about INOVIQ's situation. Taking a deeper dive, we've spotted 5 warning signs for INOVIQ you should be aware of, and 1 of them makes us a bit uncomfortable. Of course INOVIQ may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
DEA Accountability as Cannabis Research Crisis Deepens And Patients Suffer
With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health. MMJ International Holdings Issues Clarification on Irvine Labs. WASHINGTON, DC / / August 1, 2025 / MMJ International Holdings, Inc. ("MMJ") today issued a public clarification regarding prior statements about Irvine Labs, Inc., while calling for an urgent reckoning with the U.S. Drug Enforcement Administration's (DEA) catastrophic mismanagement of America's cannabis research policy. In a previous press release, MMJ referenced widespread inactivity among DEA-registered marijuana manufacturers. While these statements were intended to highlight systemic failures within the DEA's quota and licensing system, MMJ acknowledges that this language may have unintentionally caused confusion regarding Irvine Labs, Inc. MMJ hereby clarifies that Irvine Labs, Inc. is a registered DEA entity and, to the best of MMJ's current knowledge, holds valid DEA registrations. MMJ did not intend to imply that Irvine Labs is inactive or insolvent, and any interpretation suggesting otherwise is hereby retracted. This clarification, however, does not alter the underlying crisis: the DEA's marijuana manufacturing quota system is fundamentally broken. Despite a supposed expansion of DEA licenses, no registrant-except MMJ-has produced sufficient pharmaceutical-grade cannabis to support a single FDA-compliant clinical trial. The Devastating Reality: Maridose (Maine): Only 1,100 sq. ft. of space, not growing. Bright Green Corp: Surrendered its registration without ever planting a crop. Royal Emerald Pharmaceuticals: Inactive and facing financial distress. Groff NA Hemplex & Scottsdale Research Institute: No active cultivation for clinical trials. BRC: Producing quantities far below clinical thresholds. University of Mississippi: Continues to grow substandard, research-incompatible marijuana. MMJ remains the only federally compliant entity actively pursuing the cultivation of strain-specific, pharmaceutical-grade cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. Yet, for over seven years, the DEA has obstructed MMJ's efforts through unconstitutional administrative proceedings, arbitrary quotas, and a bureaucratic "Catch-22" that demands documentation (BFSA) which is unattainable without the very registration the DEA refuses to grant. A Constitutional Crisis Exposed The Supreme Court's rulings in Axon v. FTC and Jarkesy v. SEC have now exposed the DEA's internal administrative law judge (ALJ) system as an unconstitutional charade. Despite this, DEA legal counsel Aarathi Haig continues to defend a system the Department of Justice has now abandoned. Former Chief ALJ John "McLooney" Mulrooney has since retired, leaving behind what critics call a "legal dumpster fire." MMJ's legal exceptions, filed July 3, 2025, detail the agency's structural bias, retroactive sabotage, and deliberate obstruction of medical research. "We followed every law, built the FDA-inspected facility, and secured our clinical approvals," said Duane Boise, CEO of MMJ International Holdings. "What the DEA calls regulation is nothing more than bureaucratic revenge." The Time for Reckoning is Now With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health. This demands immediate action: Fire entrenched obstructionists like Thomas Prevoznik. Investigate Aarathi Haig for perpetuating unconstitutional legal processes. Transfer oversight of cannabis research to the FDA, where science-not sabotage-will guide policy. "The DEA has spent a decade fortifying a broken system that protects monopolies, obstructs innovation, and ignores public safety disasters like the Assured Testing Labs scandal in Massachusetts," said Boise. "America doesn't need another anti-marijuana crooner in a suit-it needs a leader who will stand up to this agency's sabotage and put patients first." MMJ International Holdings remains committed to factual accuracy and will continue to expose systemic failures that endanger patients, stifle science, and betray the public trust. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Trump tariffs: Which Canadian sectors will be hit, and how hard?
The bulk of Canadian trade with the U.S. still falls under the Canada-U.S.-Mexico Free Trade Deal (CUSMA). But President Donald Trump's new tariffs will hit some sectors in Canada hard. Mike Armstrong explains.
